NCT04868877 2026-02-19
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
Phase 1/2 Active not recruiting
Merus B.V.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
M.D. Anderson Cancer Center
University of Kentucky
University of California, San Diego
DEKA Biosciences